Prediction of Resistance to<sup>177</sup>Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers-Reference-Cited by-同舟云学术

Prediction of Resistance to¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Published:2023-09-28 Issue:11 Volume:64 Page:1721-1725
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Sartor Oliver,Ledet Elisa,Huang Minqui,Schwartz Jennifer,Lieberman Alex,Lewis Brian,Layton Jodi,Barata Pedro,Jang Albert,Hawkins Madeline,Pocha Olivia,Lanka Sree,Harris Kendra

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference20 articles.

1. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

2. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study;Gafita;Lancet Oncol.,2021

3. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial;Buteau;Lancet Oncol.,2022

4. Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA);Mehra;Eur Urol.,2018

5. Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation;Kwan;Front Oncol.,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review;European Urology Oncology;2024-05

2. Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer;Advances in Cancer Research;2024